Mamazhakypov, ArgenArgenMamazhakypovMaripov, AbdirashitAbdirashitMaripovSarybaev, Akpay S.Akpay S.SarybaevSchermuly, Ralph TheoRalph TheoSchermulySydykov, AkylbekAkylbekSydykov2023-09-252023-09-252023https://jlupub.ub.uni-giessen.de/handle/jlupub/18518http://dx.doi.org/10.22029/jlupub-17882Pulmonary hypertension (PH) is a pathological condition with multifactorial etiology, which is characterized by elevated pulmonary arterial pressure and pulmonary vascular remodeling. The underlying pathogenetic mechanisms remain poorly understood. Accumulating clinical evidence suggests that circulating osteopontin may serve as a biomarker of PH progression, severity, and prognosis, as well as an indicator of maladaptive right ventricular remodeling and dysfunction. Moreover, preclinical studies in rodent models have implicated osteopontin in PH pathogenesis. Osteopontin modulates a plethora of cellular processes within the pulmonary vasculature, including cell proliferation, migration, apoptosis, extracellular matrix synthesis, and inflammation via binding to various receptors such as integrins and CD44. In this article, we provide a comprehensive overview of the current understanding of osteopontin regulation and its impact on pulmonary vascular remodeling, as well as consider research issues required for the development of therapeutics targeting osteopontin as a potential strategy for the management of PH.enNamensnennung 4.0 Internationalosteopontinpulmonary hypertensionbiomarkersright heart failureddc:610